Video Experimental Relacionado
Updated: May 9, 2026
07:26
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11.9K
Evaluación cuantitativa de las asociaciones entre los polimorfismos de los genes MTR y MTRR y el riesgo de glioma
Xu Chen1, Yanping Yao2, Xi Wang3
1Center of Clinical Laboratory, First Affiliated Hospital of Soochow University, 188 Shizi Road, Suzhou, 215006, Jiangsu, People's Republic of China.
Discover oncology
|August 23, 2025
Resumen
El polimorfismo MTRR rs1801394 puede proteger contra el glioma en las poblaciones indias, pero no en las caucásicas o chinas. Este hallazgo podría ayudar en la predicción del riesgo de glioma y las estrategias de tratamiento personalizadas.
Área de la Ciencia:
- La genética
- En el campo de la oncología
- Epidemiología
Sus antecedentes:
- La susceptibilidad al glioma está influenciada por factores genéticos.
- Estudios previos sobre los polimorfismos genéticos de la metionina sintetasa (MTR) y la metionina sintetasa reductasa (MTRR) y el riesgo de glioma han mostrado resultados inconsistentes.
- Aclarar el papel de estos polimorfismos es crucial para comprender el desarrollo del glioma.
Objetivo del estudio:
- Investigar la asociación entre los polimorfismos de los genes MTR y MTRR y el riesgo de glioma.
- Proporcionar una comprensión más clara del impacto de estas variaciones genéticas en la susceptibilidad al glioma.
Principales métodos:
- Se realizó una revisión exhaustiva de la literatura utilizando las principales bases de datos.
- Los datos se recopilaron desde el inicio de las bases de datos hasta abril de 2025.
- Se emplearon técnicas de metaanálisis para sintetizar los datos.
Principales resultados:
- No se encontró una asociación significativa entre el polimorfismo MTR rs1805087 y el riesgo de glioma en todas las poblaciones.
- El polimorfismo MTRR rs1801394 mostró una asociación significativa con el riesgo de glioma en la población asiática (p < 0,05).
Conclusiones:
- El polimorfismo MTRR rs1801394 actúa como un factor protector en las poblaciones indias, pero no en las poblaciones caucásicas o chinas.
- Este polimorfismo puede servir potencialmente como un biomarcador para la predicción del riesgo de glioma.
- También puede ofrecer objetivos para tratamientos personalizados de glioma.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:12Relative Risk
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...